Changes in immunological parameters in patients with opium abuse receiving ANAR therapy.
We studied the effects of ANAR containing antibodies to morphine in ultralow doses on immunological parameters in patients with opium abuse. Changes in blood content of immunocompetent CD3+, CD16+, and HLA-DR+ cells, lymphocytes carrying receptors for serotonin and dopamine, and humoral immune factors were evaluated. As differentiated from standard preparations, ANAR possessed immunomodulatory properties, increased the content of HLA-DR+ lymphocytes and immunoglobulins in the blood, and normalized the number of CD16+ cells.
Vetlugina
T P
TP
Laboratory of Clinical Psychoneuroimmunology, Department of Addictions, Institute of Mental Health, Tomsk Research Center, Siberian Division of the Russian Academy of Medical Sciences.
Ivanova
S A
SA
Bokhan
N A
NA
Epstein
O I
OI
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology; D005260:Female; D006684:HLA-DR Antigens / Q000276:immunology; D006801:Humans; D007136:Immunoglobulins / Q000097:blood / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D009020:Morphine / Q000276:immunology; D009293:Opioid-Related Disorders / Q000188:drug therapy* / Q000276:immunology*; D017452:Receptors, IgG / Q000276:immunology; D055815:Young Adult
D000906:Antibodies; D017252:CD3 Complex; D006684:HLA-DR Antigens; D007136:Immunoglobulins; D017452:Receptors, IgG; D009020:Morphine